146 related articles for article (PubMed ID: 8162614)
1. Lysis of endothelial cells by autologous lymphokine-activated killer cells.
Kitayama J; Tsuno N; Yasuhara H; Nagawa H; Kimura W; Kuroda A; Shibata Y; Juji T; Muto T
Cancer Immunol Immunother; 1994 May; 38(5):317-22. PubMed ID: 8162614
[TBL] [Abstract][Full Text] [Related]
2. Transendothelial migration activity of lymphokine-activated killer (LAK) cells.
Kitayama J; Juji T; Atomi Y; Kuroda A; Muto T; Kobayashi M; Mitsui Y; Minami M
J Immunol; 1993 Aug; 151(3):1663-72. PubMed ID: 8335950
[TBL] [Abstract][Full Text] [Related]
3. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
Miller JS; Verfaillie C; McGlave P
Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
[TBL] [Abstract][Full Text] [Related]
4. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
5. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
Dannemann BR; Morris VA; Araujo FG; Remington JS
J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of interferon gamma-induced protection of human gliosarcoma cells from lymphokine-activated killer lysis: division of lymphokine-activated killer cells into natural killer- and T-like cells.
Kondo S; Miyatake S; Kikuchi H; Oda Y; Iwasaki K; Ohyama K; Namba Y
Neurosurgery; 1992 Sep; 31(3):534-40. PubMed ID: 1407434
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies anti-CD3, anti-TCR alpha beta and anti-CD2 act synergistically with tumor cells to stimulate lymphokine-activated killer cells and tumor-infiltrating lymphocytes to secrete interferon gamma.
Chong AS; Staren ED; Scuderi P
Cancer Immunol Immunother; 1992; 35(5):335-41. PubMed ID: 1382856
[TBL] [Abstract][Full Text] [Related]
8. Lymphokine-activated effector cells: modulation of activity by cytokines.
Mehta S; Flanagan P; Blackinton D; Wanebo H
Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer cytotoxicity against pancreas adenocarcinoma cell lines and vascular endothelial cells.
Sugiura H; Ishikura H; Omi M; Kaji M; Iwai K; Kishimoto T; Takahashi T; Kimura C; Kato H; Yoshiki T
Pathol Int; 1994 Sep; 44(9):688-96. PubMed ID: 7804431
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
[TBL] [Abstract][Full Text] [Related]
11. Lysis of pulmonary fibroblasts by lymphokine (IL-2)-activated killer cells--a mechanism affecting the human lung microenvironment?
Zambello R; Trentin L; Enthammer C; Cipriani A; Agostini C; Semenzato G
Clin Exp Immunol; 1996 Aug; 105(2):383-8. PubMed ID: 8706349
[TBL] [Abstract][Full Text] [Related]
12. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
[TBL] [Abstract][Full Text] [Related]
13. Interferon gamma enhances lymphokine-activated killer cell adhesion but not lysis of head and neck squamous cell carcinoma.
Scher RL; Carras A; Schwab D; Richtsmeier WJ; Koch WM
Arch Otolaryngol Head Neck Surg; 1995 Nov; 121(11):1271-5. PubMed ID: 7576474
[TBL] [Abstract][Full Text] [Related]
14. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells.
Zambello R; Trentin L; Feruglio C; Bulian P; Masciarelli M; Cipriani A; Agostini C; Semenzato G
Cancer Res; 1990 Mar; 50(6):1768-73. PubMed ID: 2106387
[TBL] [Abstract][Full Text] [Related]
16. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
Blanchard DK; Djeu JY
J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
[TBL] [Abstract][Full Text] [Related]
17. High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.
Koberda J; Bergmann L; Mitrou PS; Hoelzer D
J Cancer Res Clin Oncol; 1991; 117(5):425-30. PubMed ID: 1909699
[TBL] [Abstract][Full Text] [Related]
18. Lysis of herpes simplex virus-infected cells by lymphokine-activated killer cells.
Chu CT; Lee P; Lin BJ; Sun MJ; Hsieh KH
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1991 Feb; 24(1):108-18. PubMed ID: 1657543
[TBL] [Abstract][Full Text] [Related]
19. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
[TBL] [Abstract][Full Text] [Related]
20. Characterization of transendothelial migratory lymphokine-activated killer cells.
Nakano K; Eura M; Chikamatsu K; Masuyama K; Ishikawa T
Jpn J Cancer Res; 1996 Apr; 87(4):395-400. PubMed ID: 8641971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
